{
    "organizations": [],
    "uuid": "3c73d4457764a6fcc9cd990a9e85b903778431a6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-us-fda-grants-priority-review-for/brief-u-s-fda-grants-priority-review-for-daratumumab-in-front-line-multiple-myeloma-idUSASB0C1MK",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Genmab A/S:\n* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA\n* GENMAB - FDA HAS ASSIGNED PDUFA TARGET DATE OF MAY 21, 2018 TO TAKE A DECISION ON DARATUMUMAB IN THE INDICATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-20T00:47:00.000+02:00",
    "crawled": "2018-01-20T01:10:30.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "genmab",
        "fda",
        "grant",
        "priority",
        "review",
        "daratumumab",
        "front",
        "line",
        "multiple",
        "myeloma",
        "genmab",
        "fda",
        "assigned",
        "pdufa",
        "target",
        "date",
        "may",
        "take",
        "decision",
        "daratumumab",
        "indication",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}